The short answer: Not much right away, although failing to pay creditors is never a good thing for a nation's creditworthiness
Coca-Cola’s North America president, Sandy Douglas, oversees a relaunch of America’s No. 1 soft drink
Four years after the Citizens United decision, out-of-state cash is flowing down to state races
Phony phone-bill items from third-party scammers date back almost 20 years
Yves Béhar's Public Office Landscape turns the workstation into a social hub
A Bluetooth-enabled sneaker from an India-based startup doubles as a fitness tracker and personal tour guide
Critics say the agency charged with keeping regulations from burdening small companies actually serves big corporate interests
Founder: Dr. Mark Pruzanski
VC Investment over the last four quarters: $25 million
Founded in 2002, the 25-employee biopharmaceutical company is in the process of developing therapeutic treatment of chronic fibrotic and metabolic diseases. Despite the downturn, the company raised significant funding this year. Sticking to a tight budget, Intercept expects to have enough cash resources to fund its operations until 2010.
Key to startup success: "Be persistent. Intercept was founded just before the last major downturn for biotech, which lasted through 2003 and venture capital completely dried up for new early-stage startups. [We] remained passionately dedicated to the company and persisted even though it took more than a year to secure financing."